These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 9123739

  • 21. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    Köllermann J, Weikert S, Schostak M, Kempkensteffen C, Kleinschmidt K, Rau T, Pantel K.
    J Clin Oncol; 2008 Oct 20; 26(30):4928-33. PubMed ID: 18794550
    [Abstract] [Full Text] [Related]

  • 22. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study.
    Cookson MS, Sogani PC, Russo P, Sheinfeld J, Herr H, Dalbagni G, Reuter VE, Begg CB, Fair WR.
    Br J Urol; 1997 Mar 20; 79(3):432-8. PubMed ID: 9117227
    [Abstract] [Full Text] [Related]

  • 23. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
    Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP, Puras-Baez A, Lupron Depot Neoadjuvant Prostate Cancer Study Group.
    J Urol; 2002 Jan 20; 167(1):112-6. PubMed ID: 11743286
    [Abstract] [Full Text] [Related]

  • 24. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
    Cher ML, Shinohara K, Breslin S, Vapnek J, Carroll PR.
    Br J Urol; 1995 Jun 20; 75(6):771-7. PubMed ID: 7542137
    [Abstract] [Full Text] [Related]

  • 25. Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy.
    Solomon MH, McHugh TA, Dorr RP, Lee F, Siders DB.
    Clin Invest Med; 1993 Dec 20; 16(6):532-8. PubMed ID: 8013157
    [Abstract] [Full Text] [Related]

  • 26. [Impact of androgen deprivation prior to radical prostatectomy for T1, T2 prostate cancer on the likelihood of curative surgery].
    Hachiya T, Kobayashi K, Ichinose T, Ishida H, Okada K.
    Nihon Hinyokika Gakkai Zasshi; 1997 Nov 20; 88(11):936-44. PubMed ID: 9423307
    [Abstract] [Full Text] [Related]

  • 27. Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy.
    Lee F, Siders DB, McHug TA, Solomon MH, Klamerus ML.
    Anticancer Res; 1997 Nov 20; 17(3A):1507-10. PubMed ID: 9179187
    [Abstract] [Full Text] [Related]

  • 28. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
    Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D.
    Int J Radiat Oncol Biol Phys; 2001 Aug 01; 50(5):1243-52. PubMed ID: 11483335
    [Abstract] [Full Text] [Related]

  • 29. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
    Gomella LG, Liberman SN, Mulholland SG, Petersen RO, Hyslop T, Corn BW.
    Urology; 1996 Jun 01; 47(6):870-7. PubMed ID: 8677579
    [Abstract] [Full Text] [Related]

  • 30. Neoadjuvant hormonal deprivation before radical prostatectomy.
    Sassine AM, Schulman CC.
    Eur Urol; 1993 Jun 01; 24 Suppl 2():46-50. PubMed ID: 7505231
    [Abstract] [Full Text] [Related]

  • 31. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Urology; 1996 Jan 01; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [Abstract] [Full Text] [Related]

  • 32. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.
    Meyer F, Moore L, Bairati I, Lacombe L, Têtu B, Fradet Y.
    J Urol; 1999 Dec 01; 162(6):2024-8. PubMed ID: 10569561
    [Abstract] [Full Text] [Related]

  • 33. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
    Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B.
    Clin Invest Med; 1993 Dec 01; 16(6):499-509. PubMed ID: 8013155
    [Abstract] [Full Text] [Related]

  • 34. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer.
    Dalkin BL, Ahmann FR, Nagle R, Johnson CS.
    J Urol; 1996 Apr 01; 155(4):1357-60. PubMed ID: 8632574
    [Abstract] [Full Text] [Related]

  • 35. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
    Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.
    Cochrane Database Syst Rev; 2006 Oct 18; 2006(4):CD006019. PubMed ID: 17054269
    [Abstract] [Full Text] [Related]

  • 36. Neoadjuvant flutamide monotherapy for locally confined prostate cancer.
    Yoshimura K, Sumiyoshi Y, Hashimura T, Ueda T, Kamiryo Y, Yamamoto A, Arai Y.
    Int J Urol; 2003 Apr 18; 10(4):190-5. PubMed ID: 12657097
    [Abstract] [Full Text] [Related]

  • 37. Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy.
    Gao X, Zhou T, Tang YJ, Lu X, Sun YH.
    Asian J Androl; 2009 Jan 18; 11(1):127-30. PubMed ID: 19050694
    [Abstract] [Full Text] [Related]

  • 38. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD.
    J Urol; 1996 Jan 18; 155(1):213-9. PubMed ID: 7490838
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
    Andros EA, Danesghari F, Crawford ED.
    Clin Invest Med; 1993 Dec 18; 16(6):510-5. PubMed ID: 7516835
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.